|Publication Date:||February 01, 2015|
The UAE pharma and healthcare sector has witnessed exponential growth in the recent times. This has been contributed by various factors, including increased government spending, insurance penetration and diverse investment options available in the market. However, it appears that many international companies while focussed on benefiting from the market growth are oblivious on the compliance front. In terms of anti-corruption, their attention is confined to the US Federal Corrupt Practices Act (FCPA) or the UK Bribery Act and they are unaware of the anti-corruption laws in the UAE.
Author: Faizal Latheef
Faizal is renowned for his expertise in corporate and commercial law. He represents and advises clients on a wide variety of matters including Foreign Investments, Joint Ventures, Mergers and Acquisitions, Corporate Restructuring, Distribution & Franchising, Anti-Corruption & Compliance, Cross-Border Transactions, Employment and Wills.